Dec 6, 2016

Oncolytics Biotech® Inc. Collaborators Present Initial Results from REO 019 Study in Multiple Myeloma Combining REOLYSIN®, Bortezomib and Dexamethasone at the ASH Annual Meeting

Nov 10, 2016

Oncolytics Biotech® Inc. Announces Appointment of New Chief Medical Officer

Nov 3, 2016

Oncolytics Biotech® Inc. Announces 2016 Third Quarter Results

Nov 2, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Management Team Changes

Oct 18, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 2016 BIO Investor Forum

Aug 30, 2016

Media Advisory - Oncolytics Biotech® Inc. Announces Participation in the 4th Annual Immuno-Oncology Summit

Aug 10, 2016

MEDIA ADVISORY - Oncolytics Biotech® Inc. Announces Participation in the Canaccord Genuity 36th Annual Growth Conference

Aug 10, 2016

Oncolytics Biotech® Inc. Reports Additional Data from Randomized Phase II Study of REOLYSIN® in Non-Small Cell Lung Cancer

Aug 4, 2016

Oncolytics Biotech® Inc. Announces 2016 Second Quarter Results

Jun 29, 2016

Oncolytics Biotech® Inc. Announces Phase 2 Study in Female Patients with Colorectal Cancer Metastatic to the Liver